Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Hillmen

Showing results (31-40 of 52) with videos related to

Pageof 6
Sort By:
British Journal of Haematology|October 16, 1999
The PNH phenotype cells that emerge in most patients after CAMPATH-1H therapy are present prior to treatmentA C Rawstron, S J Rollinson, S Richards, et al.
Blood|October 15, 1994
Expression of recombinant transmembrane CD59 in paroxysmal nocturnal hemoglobinuria B cells confers resistance to human complementR P Rother, S A Rollins, J Mennone, et al.
British Journal of Clinical Pharmacology|May 18, 2007
Population pharmacokinetics-pharmacodynamics of alemtuzumab (Campath) in patients with chronic lymphocytic leukaemia and its link to treatment responseD R Mould, A Baumann, J Kuhlmann, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 22, 2020
Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upB Eichhorst, T Robak, E Montserrat, et al.
Internal Medicine Journal|August 23, 2012
Cross-sectional validation study of patient-reported outcomes in patients with paroxysmal nocturnal haemoglobinuriaI Weitz, G Meyers, T Lamy, et al.
Oncogene|April 5, 2016
An ultra-deep sequencing strategy to detect sub-clonal TP53 mutations in presentation chronic lymphocytic leukaemia cases using multiple polymerasesL Worrillow, P Baskaran, M A Care, et al.
Leukemia|October 22, 2005
The evolving role of alemtuzumab in management of patients with CLLS Faderl, S Coutré, J C Byrd, et al.
Internal Medicine Journal|June 16, 2016
Changing prognosis in paroxysmal nocturnal haemoglobinuria disease subcategories: an analysis of the International PNH RegistryG Socié, H Schrezenmeier, P Muus, et al.
Blood|June 22, 2001
Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapyA C Rawstron, B Kennedy, P A Evans, et al.
Leukemia|February 21, 2017
Results of the randomized phase IIB ADMIRE trial of FCR with or without mitoxantrone in previously untreated CLLT Munir, D R Howard, L McParland, et al.
Pageof 6

Showing results (31-40 of 52) with videos related to

Sort By:
Pageof 6
British Journal of Haematology|October 16, 1999
The PNH phenotype cells that emerge in most patients after CAMPATH-1H therapy are present prior to treatmentA C Rawstron, S J Rollinson, S Richards, et al.
Blood|October 15, 1994
Expression of recombinant transmembrane CD59 in paroxysmal nocturnal hemoglobinuria B cells confers resistance to human complementR P Rother, S A Rollins, J Mennone, et al.
British Journal of Clinical Pharmacology|May 18, 2007
Population pharmacokinetics-pharmacodynamics of alemtuzumab (Campath) in patients with chronic lymphocytic leukaemia and its link to treatment responseD R Mould, A Baumann, J Kuhlmann, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 22, 2020
Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upB Eichhorst, T Robak, E Montserrat, et al.
Internal Medicine Journal|August 23, 2012
Cross-sectional validation study of patient-reported outcomes in patients with paroxysmal nocturnal haemoglobinuriaI Weitz, G Meyers, T Lamy, et al.
Oncogene|April 5, 2016
An ultra-deep sequencing strategy to detect sub-clonal TP53 mutations in presentation chronic lymphocytic leukaemia cases using multiple polymerasesL Worrillow, P Baskaran, M A Care, et al.
Leukemia|October 22, 2005
The evolving role of alemtuzumab in management of patients with CLLS Faderl, S Coutré, J C Byrd, et al.
Internal Medicine Journal|June 16, 2016
Changing prognosis in paroxysmal nocturnal haemoglobinuria disease subcategories: an analysis of the International PNH RegistryG Socié, H Schrezenmeier, P Muus, et al.
Blood|June 22, 2001
Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapyA C Rawstron, B Kennedy, P A Evans, et al.
Leukemia|February 21, 2017
Results of the randomized phase IIB ADMIRE trial of FCR with or without mitoxantrone in previously untreated CLLT Munir, D R Howard, L McParland, et al.
Pageof 6